Skip to main navigation Skip to search Skip to main content

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

  • Iago Pinal-Fernandez
  • , Angela Quintana
  • , Jose Cesar Milisenda
  • , Maria Casal-Dominguez
  • , Sandra Muñoz-Braceras
  • , Assia Derfoul
  • , Jiram Torres-Ruiz
  • , Katherine Pak
  • , Stefania Dell'Orso
  • , Faiza Naz
  • , Gustavo Gutierrez-Cruz
  • , Margherita Milone
  • , Shahar Shelly
  • , Yaiza Duque-Jaimez
  • , Ester Tobias-Baraja
  • , Ana Matas-Garcia
  • , Gloria Garrabou
  • , Joan Padrosa
  • , Javier Ros
  • , Ernesto Trallero-Araguás
  • Brian Walitt, Lisa Christopher-Stine, Thomas E. Lloyd, Chen Zhao, Shannon Swift, Arun Rajan, Josep Maria Grau-Junyent, Albert Selva-O'Callaghan, Teerin Liewluck, Andrew Lee Mammen

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives Inflammatory myopathy or myositis is a heterogeneous family of immune-mediated diseases including dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotising myopathy (IMNM) and inclusion body myositis (IBM). Immune checkpoint inhibitors (ICIs) can also cause myositis (ICI-myositis). This study was designed to define gene expression patterns in muscle biopsies from patients with ICI-myositis. Methods Bulk RNA sequencing was performed on 200 muscle biopsies (35 ICI-myositis, 44 DM, 18 AS, 54 IMNM, 16 IBM and 33 normal muscle biopsies) and single nuclei RNA sequencing was performed on 22 muscle biopsies (seven ICI-myositis, four DM, three AS, six IMNM and two IBM). Results Unsupervised clustering defined three distinct transcriptomic subsets of ICI-myositis: ICI-DM, ICI-MYO1 and ICI-MYO2. ICI-DM included patients with DM and anti-TIF1γautoantibodies who, like DM patients, overexpressed type 1 interferon-inducible genes. ICI-MYO1 patients had highly inflammatory muscle biopsies and included all patients that developed coexisting myocarditis. ICI-MYO2 was composed of patients with predominant necrotising pathology and low levels of muscle inflammation. The type 2 interferon pathway was activated both in ICI-DM and ICI-MYO1. Unlike the other types of myositis, all three subsets of ICI-myositis patients overexpressed genes involved in the IL6 pathway. Conclusions We identified three distinct types of ICI-myositis based on transcriptomic analyses. The IL6 pathway was overexpressed in all groups, the type I interferon pathway activation was specific for ICI-DM, the type 2 IFN pathway was overexpressed in both ICI-DM and ICI-MYO1 and only ICI-MYO1 patients developed myocarditis.

Original languageEnglish (US)
Pages (from-to)829-836
Number of pages8
JournalAnnals of the rheumatic diseases
Volume82
Issue number6
DOIs
StatePublished - Jun 1 2023

Keywords

  • autoimmune diseases
  • dermatomyositis
  • polymyositis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis'. Together they form a unique fingerprint.

Cite this